▲ +151.68% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Atossa Therapeutics in the last 3 months. The average price target is $7.50, with a high forecast of $8.00 and a low forecast of $7.00. The average price target represents a 151.68% upside from the last price of $2.98.
The current consensus among 2 contributing investment analysts is to buy stock in Atossa Therapeutics. This Buy consensus rating has held steady for over two years.
Atossa Therapeutics, Inc. develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the United States. The company's lead program is the development of Endoxifen, an active metabolite of tamoxifen which is in Phase II studies to treat and prevent breast cancer. It is also developing intraductal microcatheter technology to target the delivery of therapies, including fulvestrant, immunotherapies, and Chimeric Antigen Receptor T-cell therapies, directly to the site of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2009 and is headquartered in Seattle, Washington.